Cost-effectiveness of natalizumab in multiple sclerosis

Expert Review of Pharmacoeconomics and Outcomes Research

Volumn 8, Issue 1, 2008, Pages 11-21

  Holmoy, Trygve ^a,b   Celius, Elisabeth Gulowsen ^a  

^a ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF OSLO   (Norway)

Author keywords

Cost effectiveness; Multiple sclerosis; Natalizumab; Pharmacoeconomics; Quality of life

Indexed keywords

ALEMTUZUMAB; BETA INTERFERON; BETA1A INTERFERON; CLADRIBINE; FINGOLIMOD; GLATIRAMER; INTERFERON BETA SERINE; MITOXANTRONE; NATALIZUMAB; PLACEBO; RITUXIMAB; TERIFLUNOMIDE;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; COST OF ILLNESS; COST UTILITY ANALYSIS; DRUG APPROVAL; DRUG COST; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EARLY INTERVENTION; EVIDENCE BASED MEDICINE; HEALTH CARE COST; HEALTH INSURANCE; HUMAN; LONG TERM CARE; MEDICAL DECISION MAKING; MONOTHERAPY; MULTIPLE SCLEROSIS; PHYSICAL DISABILITY; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; RECURRENCE RISK; RECURRENT DISEASE; RISK REDUCTION; SOCIOECONOMICS; TREATMENT DURATION;

EID: 40749096370     PISSN: 14737167     EISSN: 17448379     Source Type: Journal    
DOI: 10.1586/14737167.8.1.11     Document Type: Article

References (55)

1. Ann MF, Rudick RA. Drug insight: interferon treatment in multiple sclerosis. Nat. Clin. Pract. Neurol. 2(1), 34-44 (2006).
2. Weinshenker BG. The natural history of multiple sclerosis. Neurol Clin. 13(1), 119-146(1995).
3. Vukusic S, Confavreux C. Natural history of multiple sclerosis: risk factors and prognostic indicators. Curr. Opin. Neurol. 20(3), 269-274 (2007).
4. Boeije HR, Janssens AC. 'It might happen or it might not': how patients with multiple sclerosis explain their perception of prognostic risk. Soc. Sci. Med. 59(4), 861-868 (2004).
5. Mitchell AJ, Benito-Leòn J, Gonzàlez JM, Rivera-Navarro J. Quality of life and its assessment in multiple sclerosis: integrating physical and psychological components of wellbeing. Lancet Neurol. 4(9), 556-566 (2005).
6. Rothwell PM, McDowell Z, Wong CK, Dorman PJ. Doctors and patients don't agree: cross sectional study of patients' and doctors' perceptions and assessments of disability in multiple sclerosis. Br. Med. J. 314(7094), 1580-1583(1997).
7. Compston A, Coles A. Multiple sclerosis. Lancet 359(9313), 1221-1231 (2002).
8. Pugliatti M, Rosati G, Carton H et al. The epidemiology of multiple sclerosis in Europe. 13(7), 700-722 (2006).
9. Hader WJ, Yee IM. Incidence and prevalence of multiple sclerosis in Saskatoon, Saskatchewan. Neurology 69(12), 1224-1229 (2007).
10. Orton SM, Herrera BM, Yee IM et al. Sex ratio of multiple sclerosis in Canada: a longitudinal study. Lancet Neurol. 5(11), 932-936 (2006).
11. Orlewska E. Economic burden of multiple sclerosis: what can we learn from cost-of-illness studies? Expert Rev. Pharmacoeconomics Outcomes Res. 6(2), 145-154 (2006).
12. Leary SM, Thompson AJ. Primary progressive multiple sclerosis: current and future treatment options. CNS Drugs 19(5), 369-376 (2005).
13. Rice GP, Incorvaia B, Munari L et al. Interferon in relapsing-remitting multiple sclerosis. Cochrane Database Syst Rev. 4, CD002002 (2001).
14. Munari L, Lovati R, Boiko A. Therapy with glatiramer acetate for multiple sclerosis. Cochrane Database Syst. Rev. 1, CD004678 (2004).
15. Martinelli BF, Rovaris M, Capra R, Comi G. Mitoxantrone for multiple sclerosis. Cochrane Database Syst. Rev. 4, CD002127 (2005).
16. Kobelt G, Pugliatti M. Cost of multiple sclerosis in Europe. Eur. J. Neurol. 12(Suppl. 1), 63-67 (2005).
17. Kobelt G, Berg J, Lindgren P, Fredrikson S, Jonsson B. Costs and quality of life of patients with multiple sclerosis in Europe. J. Neurol. Neurosurg. Psychiatry 77(8), 918-926 (2006).
18. Sobocki P, Pugliatti M, Lauer K, Kobelt G. Estimation of the cost of MS in Europe: extrapolations from a multinational cost study. Mult. Scler. 13(8), 1054-1064 (2007).
19. Steinman L. Blocking adhesion molecules as therapy for multiple sclerosis: natalizumab. Nat. Rev. Drug Discov. 4(6), 510-518 (2005).
20. Polman CH, O'Connor PW, Havrdova E et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N. Engl. J. Med. 354(9), 899-910 (2006).
21. Yousry TA, Major EO, Ryschkewitsch C et al. Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy. N. Engl. J. Med. 354(9), 924-933 (2006).
22. Panzara MA, Belcher G, Kooijmans M, Kim R, Lynn F, Bozic C. Use of natalizumab in patients with relapsing multiple sclerosis: updated safety results from TOUCH and TYGRIS. Presented at: 23rd Congress of the European Committee for Treatment and Research in Multiple Sclerosis. Prague, Czech Republic, 11-14 October 2007.
23. Hauser SL, Johnston SC. Recombinant therapeutics: from bench to bedside (if your health plan concurs). Ann. Neurol. 60(5), A10-A11 (2006).
24. Drummond M, O'Brien B, Stoddart G, Torrance G (Eds). Methods for the economic evaluation of health care programmes. Oxford University Press, Oxford, UK (1997).
25. Philips Z, Ginnelly L, Sculpher M et al. Review of guidelines for good practice in decision-analytic modelling in health technology assessment. Health Technol. Assess. 8(36), III-XI, 1-158 (2004).
26. Johnson KP. Natalizumab (Tysabri) treatment for relapsing multiple sclerosis. Neurologist 13(4), 182-187(2007).
27. Ransohoff RM. Natalizumab for multiple sclerosis. N. Engl. J. Med. 356(25), 2622-2629 (2007).
28. Rudick RA, Stuart WH, Calabresi PA et al. Natalizumab plus interferon β-1a for relapsing multiple sclerosis. N. Engl. J. Med. 354(9), 911-923 (2006).
29. Rudick RA, Miller D, Hass S et al. Health-related quality of life in multiple sclerosis: effects of natalizumab. Ann. Neurol. 62(4), 335-346 (2007).
30. Weinstein MC, Siegel JE, Gold MR, Kamlet MS, Russell LB. Recommendations of the panel on cost-effectiveness in health and medicine. JAMA 276(15), 1253-1258 (1996).
31. Kobelt G. Health economic issues in MS. Int. MS J. 13(1), 17-26(2006).
32. Ebers GC. Natural history of multiple sclerosis. J. Neurol. Neurosurg. Psychiatry 71 (Suppl. 2), II16-II19 (2001).
33. Chilcott J, McCabe C, Tappenden P et al. Modelling the cost effectiveness of interferon β and glatiramer acetate in the management of multiple sclerosis. Commentary: evaluating disease modifying treatments in multiple sclerosis. Br. Med. J. 326(7388), 522-528 (2003).
34. Orme M, Kerrigan J, Tyas D, Russell N, Nixon R. The effect of disease, functional status, and relapses on the utility of people with multiple sclerosis in the UK. Value Health 10(1), 54-60 (2007).
35. Lang DL, Lopert R. Hill SR. Use of pharmacoeconomics in prescribing research. Part 5: modelling - beyond clinical trials. J. Clin. Pharm. Ther. 28(5), 433-439 (2003).
36. Hobart J, Kalkers N, Barkhof F, Uitdehaag B, Polman C, Thompson A. Outcome measures for multiple sclerosis clinical trials: relative measurement precision of the Expanded Disability Status Scale and Multiple Sclerosis Functional Composite. Mult. Scler. 10(1), 41-46 (2004).
37. Chiao E, Meyer K. Cost-effectiveness of disease modifying agents for the treatment of multiple sclerosis. Presented at: The Academy of Managed Care (AMCP) Educational Confirence, Chicago, IL, USA (2006) (Abstract).
38. Chiao E, Meyer K. Cost-effectiveness of disease-modifying drugs for the treatment of relapsing remitting multiple sclerosis. J. Manag. Care Pharm. 12(7), 598-588 (2006).
39. Al-Sabbagh A, Papshev D. Comparative analysis of multiple sclerosis cost effectiveness models: focus on the managed care perspective.Presented at: The Academy of Managed Care Pharmacy Hosts 19th Annual Meeting & Showcase, San Diego CA, USA April 11-14, 2007.
40. Jacobs LD, Cookfair DL, Rudick RA et al. Intramuscular interferon β-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). Ann. Neurol. 39(3), 285-294 (1996).
41. IFNB Multiple Sclerosis Study Group. Interferon β-lb is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. 1993. Neurology 57(12 Suppl. 5), S3-S9 (2001).
42. Johnson KP, Brooks BR, Cohen JA et al. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a Phase III multicenter, double-blind, placebo-controlled trial. Neurology 45(7), 1268-1276 (1995).
43. [No authors listed]. Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon β-1a Subcutaneously in Multiple Sclerosis) Study Group. Lancet 352(9139), 1498-4504 (1998).
44. Weinshenker BG, Bass B, Rice GP et al. The natural history of multiple sclerosis: a geographically based study. I. Clinical course and disability. Brain 112 (1), 133-146 (1989).
45. Confavreux C, Vukusic S. Natural history of multiple sclerosis: a unifying concept. Brain 129(3), 606-616 (2006).
46. Kremenchutzky M, Rice GP, Baskerville J, Wingerchuk DM, Ebers GC. The natural history of multiple sclerosis: a geographically based study 9: observations on the progressive phase of the disease. Brain 129(3), 584-594 (2006).
47. Phillips CJ. The cost of multiple sclerosis and the cost effectiveness of disease-modifying agents in its treatment. CNS Drugs 18(9), 561-574 (2004).
48. Prosser LA, Kuntz KM, Bar-Or A, Weinstein MC. Cost - effectiveness of interferon β-1a, interferon β-1b, and glatiramer acetate in newly diagnosed non-primary progressive multiple sclerosis. Value Health 7(5), 554-568 (2004).
49. Bell C, Graham J, Eamshaw S, Oleen-Burkey M, Castelli-Haley J, Johnson K. Cost-effectiveness of four immunomodulatory therapies for relapsi-remitting multiple sclerosis: a Markov model based on long-term clinical data. J. Manag. Care Pharm. 13(3), 245-261 (2007).
50. Curtiss FR. Pharmacoeconomic modeling of drug therapies for multiple sclerosis - are we building houses on sand? J. Manag. Care Pharm. 13(3), 287-289 (2007).
51. Grima DT, Torrance GW, Francis G, Rice G, Rosner AJ, Lafortune L. Cost and health related quality of life consequences of multiple sclerosis. Mult. Scler. 6(2), 91-98 (2000).
52. Berg J, Lindgren P, Fredrikson S, Kobelt G. Costs and quality of life of multiple sclerosis in Sweden. Eur. J. Health Econ. 7(Suppl. 2), S75-S85 (2006).
53. Pittock SJ, Mayr WT, McClelland RL et al. Change in MS-related disability in a population-based cohort: a 10-year follow-up study. Neurology 62(1), 51-59 (2004).
54. Kappos L, Bates D, Hartung HP et al. Natalizumab treatment for multiple sclerosis: recommendations for patient selection and monitoring. Lancet Neurol. 6(5), 431-441 (2007).
55. Simpson BS, Coles AJ. Rationale for cytotoxic monoclonal antibodies in MS. Int. MS J. 14(2), 48-56 (2007).